XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism

Cancer Letters

Volumn 351, Issue 1, 2014, Pages 151-161

  Sureban, Sripathi M ^a,b,c   May, Randal ^a,b   Weygant, Nathaniel ^a   Qu, Dongfeng ^a   Chandrakesan, Parthasarathy ^a   Bannerman Menson, Eddie ^d   Ali, Naushad ^a,d   Pantazis, Panayotis ^d   Westphalen, Christoph B ^e   Wang, Timothy C ^e   Houchen, Courtney W ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Peggy and Charles Stephenson Oklahoma Cancer Center   (United States)

^d COARE Biotechnology Inc ^*  (United States)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

Angiogenic factors; DCLK1; Epithelial mesenchymal transition; Pluripotency factors; XMD8 92

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; DOUBLECORTIN LIKE KINASE 1; K RAS PROTEIN; KRUPPEL LIKE FACTOR 4; LIN28 PROTEIN; MICRORNA; MICRORNA 143; MICRORNA 144; MICRORNA 145; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA LET 7A; MYC PROTEIN; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHOTRANSFERASE; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; XMD 8 92; ZEB2 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE; P21 GENE; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION;

ANGIOGENIC FACTORS; DCLK1; EPITHELIAL-MESENCHYMAL TRANSITION; PLURIPOTENCY FACTORS; XMD8-92;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; RECEPTOR, NOTCH1; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903708048     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.05.011     Document Type: Article

References (61)

1. Abel E.V., Simeone D.M. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology 2013, 144:1241-1248.
2. Andresen K., Boberg K.M., Vedeld H.M., Honne H., Hektoen M., Wadsworth C.A., Clausen O.P., Karlsen T.H., Foss A., Mathisen O., Schrumpf E., Lothe R.A., Lind G.E. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics: Official J. DNA Methylation Soc. 2012, 7.
3. Bailey J.M., Alsina J., Rasheed Z.A., McAllister F.M., Fu Y.Y., Plentz R., Zhang H., Pasricha P.J., Bardeesy N., Matsui W., Maitra A., Leach S.D. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in pre-invasive pancreatic cancer. Gastroenterology 2014, 146:245-256.
4. Chen X., Guo X., Zhang H., Xiang Y., Chen J., Yin Y., Cai X., Wang K., Wang G., Ba Y., Zhu L., Wang J., Yang R., Zhang Y., Ren Z., Zen K., Zhang J., Zhang C.Y. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28:1385-1392.
5. Chen Y., Xie D., Yin Li W., Man Cheung C., Yao H., Chan C.Y., Chan C.Y., Xu F.P., Liu Y.H., Sung J.J., Kung H.F. RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett. 2010, 297:109-116.
6. Chen Y.C., Hsu H.S., Chen Y.W., Tsai T.H., How C.K., Wang C.Y., Hung S.C., Chang Y.L., Tsai M.L., Lee Y.Y., Ku H.H., Chiou S.H. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PloS One 2008, 3:e2637.
7. Choi Y.C., Yoon S., Jeong Y., Yoon J., Baek K. Regulation of vascular endothelial growth factor signaling by miR-200b. Mol. Cells 2011, 32:77-82.
8. Chugh R., Sangwan V., Patil S.P., Dudeja V., Dawra R.K., Banerjee S., Schumacher R.J., Blazar B.R., Georg G.I., Vickers S.M., Saluja A.K. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci. Translational Med. 2012, 4:156ra139.
9. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
10. Corbo V., Tortora G., Scarpa A. Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr. Drug Targets 2012, 13:744-752.
11. Deng X., Yang Q., Kwiatkowski N., Sim T., McDermott U., Settleman J.E., Lee J.D., Gray N.S. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACS Med. Chem. Lett. 2011, 2:195-200.
12. Diehn M., Clarke M.F. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J. Natl. Cancer Inst. 2006, 98:1755-1757.
13. Esau C., Kang X., Peralta E., Hanson E., Marcusson E.G., Ravichandran L.V., Sun Y., Koo S., Perera R.J., Jain R., Dean N.M., Freier S.M., Bennett C.F., Lollo B., Griffey R. MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem. 2004, 279:52361-52365.
14. Feng X., Wang Z., Fillmore R., Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014, 344:166-173.
15. Gagliardi G., Goswami M., Passera R., Bellows C.F. DCLK1 immunoreactivity in colorectal neoplasia. Clin. Exp. Gastroenterol. 2012, 5:35-42.
16. Guo Y., Ying L., Tian Y., Yang P., Zhu Y., Wang Z., Qiu F., Lin J. MiR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J. 2013, 280:4531-4538.
17. Herreros-Villanueva M., Zhang J.S., Koenig A., Abel E.V., Smyrk T.C., Bamlet W.R., de Narvajas A.A., Gomez T.S., Simeone D.M., Bujanda L., Billadeau D.D. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013, 2:e61.
18. Hu G., Li F., Ouyang K., Xie F., Tang X., Wang K., Han S., Jiang Z., Zhu M., Wen D., Qin X., Zhang L. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype. Int. J. Oncol. 2012, 40:798-806.
19. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
20. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011, 61:69-90.
21. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59(2009):225-249.
22. Jimeno A., Feldmann G., Suarez-Gauthier A., Rasheed Z., Solomon A., Zou G.M., Rubio-Viqueira B., Garcia-Garcia E., Lopez-Rios F., Matsui W., Maitra A., Hidalgo M. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther. 2009, 8:310-314.
23. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. New Engl. J. Med. 2006, 355:1253-1261.
24. Kent O.A., Chivukula R.R., Mullendore M., Wentzel E.A., Feldmann G., Lee K.H., Liu S., Leach S.D., Maitra A., Mendell J.T. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010, 24:2754-2759.
25. Kim M.H., Cierpicki T., Derewenda U., Krowarsch D., Feng Y., Devedjiev Y., Dauter Z., Walsh C.A., Otlewski J., Bushweller J.H., Derewenda Z.S. The DCX-domain tandems of doublecortin and doublecortin-like kinase. Nat. Struct. Biol. 2003, 10:324-333.
26. King J.B., von Furstenberg R.J., Smith B.J., McNaughton K.K., Galanko J.A., Henning S.J. CD24 can be used to isolate Lgr5+ putative colonic epithelial stem cells in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303:G443-G452.
27. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283:14910-14914.
28. Krejs G.J. Pancreatic cancer: epidemiology and risk factors. Digest. Dis. 2010, 28:355-358.
29. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
30. Lin P.T., Gleeson J.G., Corbo J.C., Flanagan L., Walsh C.A. DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization. J. Neurosci. 2000, 20:9152-9161.
31. Maitra A., Hruban R.H. Pancreatic cancer. Annu. Rev. Pathol. 2008, 3:157-188.
32. May R., Riehl T.E., Hunt C., Sureban S.M., Anant S., Houchen C.W. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells 2008, 26:630-637.
33. May R., Sureban S.M., Hoang N., Riehl T.E., Lightfoot S.A., Ramanujam R., Wyche J.H., Anant S., Houchen C.W. Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells 2009, 27:2571-2579.
34. May R., Sureban S.M., Lightfoot S.A., Hoskins A.B., Brackett D.J., Postier R.G., Ramanujam R., Rao C.V., Wyche J.H., Anant S., Houchen C.W. Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G303-G310.
35. Michl P., Gress T.M. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013, 62:317-326.
36. Miele E., Spinelli G.P., Miele E., Di Fabrizio E., Ferretti E., Tomao S., Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int. J. Nanomed. 2012, 7:3637-3657.
37. Nakanishi Y., Seno H., Fukuoka A., Ueo T., Yamaga Y., Maruno T., Nakanishi N., Kanda K., Komekado H., Kawada M., Isomura A., Kawada K., Sakai Y., Yanagita M., Kageyama R., Kawaguchi Y., Taketo M.M., Yonehara S., Chiba T. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat. Genetics 2013, 45:98-103.
38. Patel K., Kollory A., Takashima A., Sarkar S., Faller D.V., Ghosh S.K. MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett. 2014, 347:54-64.
39. Paulson A.S., Tran Cao H.S., Tempero M.A., Lowy A.M. Therapeutic advances in pancreatic cancer. Gastroenterology 2013, 144:1316-1326.
40. Peng X., Guo W., Liu T., Wang X., Tu X., Xiong D., Chen S., Lai Y., Du H., Chen G., Liu G., Tang Y., Huang S., Zou X. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PloS One 2011, 6:e20341.
41. Prasad N.B., Biankin A.V., Fukushima N., Maitra A., Dhara S., Elkahloun A.G., Hruban R.H., Goggins M., Leach S.D. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 2005, 65:1619-1626.
42. Roybal J.D., Zang Y., Ahn Y.H., Yang Y., Gibbons D.L., Baird B.N., Alvarez C., Thilaganathan N., Liu D.D., Saintigny P., Heymach J.V., Creighton C.J., Kurie J.M. MiR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol. Cancer Res.: MCR 2011, 9:25-35.
43. Sachdeva M., Zhu S., Wu F., Wu H., Walia V., Kumar S., Elble R., Watabe K., Mo Y.Y. P53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3207-3212.
44. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
45. Shi B., Sepp-Lorenzino L., Prisco M., Linsley P., deAngelis T., Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J. Biol. Chem. 2007, 282:32582-32590.
46. Sultana A., Smith C.T., Cunningham D., Starling N., Neoptolemos J.P., Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol. 2007, 25:2607-2615.
47. Sureban S.M., Johnson J.J., Houchen C.W. Cancer stem cells and pluripotency. Pancreatic Disord. Ther. 2012, 02.
48. Sureban S.M., May R., Lightfoot S.A., Hoskins A.B., Lerner M., Brackett D.J., Postier R.G., Ramanujam R., Mohammed A., Rao C.V., Wyche J.H., Anant S., Houchen C.W. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011, 71:2328-2338.
49. Sureban S.M., May R., Mondalek F.G., Qu D., Ponnurangam S., Pantazis P., Anant S., Ramanujam R.P., Houchen C.W. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J. Nanobiotechnol. 2011, 9:40.
50. Sureban S.M., May R., Qu D., Weygant N., Chandrakesan P., Ali N., Lightfoot S.A., Pantazis P., Rao C.V., Postier R.G., Houchen C.W. DCLK1 regulates pluripotency and angiogenic factors via microrna-dependent mechanisms in pancreatic cancer. PloS One 2013, 8:e73940.
51. Sureban S.M., May R., Ramalingam S., Subramaniam D., Natarajan G., Anant S., Houchen C.W. Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 2009, 137:649-659.
52. Wang H., Wang F., Tao X., Cheng H. Ammonia-containing dimethyl sulfoxide: an improved solvent for the dissolution of formazan crystals in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Anal. Biochem. 2012, 421:324-326.
53. Wei D., Wang L., Kanai M., Jia Z., Le X., Li Q., Wang H., Xie K. KLF4alpha up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology 2010, 139:2135-2145.
54. Wen J., Park J.Y., Park K.H., Chung H.W., Bang S., Park S.W., Song S.Y. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas 2010, 39:622-626.
55. Westphalen C.B., Asfaha S., Hayakawa Y., Takemoto Y., Lukin D.J., Nuber A.H., Brandtner A., Setlik W., Remotti H., Muley A., Chen X., May R., Houchen C.W., Fox J.G., Gershon M.D., Quante M., Wang T.C. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J. Clin. Invest. 2014, 124:1283-1295.
56. C.B. Westphalen, Quante, M., Worthley, D.L., Asfaha, S., Houchen, C.W., May, R., Remotti, H., Olive, K.P., Wang, T.C., Dclk1 identifie adult pancreatic stem and cancer initiating cells, in: AACR special conference, Cancer Research, June 2012.
57. Westphalen C.B., Quante M., Worthley D.L., Asfaha S., Remotti H., Olive K.P., Wang T.C. DCLK1 labels adult progenitor and cancer initiating cells in the pancreas. Gastroenterology 2012, S-50.
58. C.B. Westphalen, Quante, M., Worthley, D.L., Asfaha, S., Remotti, H., Olive, K.P., Wang, T.C., Dclk1 labels quiescent pancreatic progenitor and cancer initiating cells, in: AACR 103rd Annual Meeting, Cancer Research, Chicago, IL, 2012, pp. Supplement 1.
59. Wolfgang C.L., Herman J.M., Laheru D.A., Klein A.P., Erdek M.A., Fishman E.K., Hruban R.H. Recent progress in pancreatic cancer. CA: Cancer J. Clin. 2013, 63:318-348.
60. Xia H., Ng S.S., Jiang S., Cheung W.K., Sze J., Bian X.W., Kung H.F., Lin M.C. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem. Biophys. Res. Commun. 2010, 391:535-541.
61. Yang Q., Deng X., Lu B., Cameron M., Fearns C., Patricelli M.P., Yates J.R., Gray N.S., Lee J.D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010, 18:258-267.